Stockreport

New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

CELGENE  (CELG) 
Last celgene earnings: 10/31 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celgene.com
PDF Ozanimod showed effects on cognitive processing speed in a post hoc analysis of 12-month data from SUNBEAMâ„¢ pivotal trial In separate post hoc an [Read more]